Zanamivir
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
* Major Indication: [[Influenza]] Infection | * Major Indication: [[Influenza]] Infection | ||
* Drug Class: [[Neuraminidase]] Inhibitor | * Drug Class: [[Neuraminidase]] Inhibitor | ||
| - | * Date of FDA Approval: | + | * Date of FDA Approval (Patent Expiration): 1999 (2016) |
* 2009 Sales:$1.1 Billion | * 2009 Sales:$1.1 Billion | ||
| - | * Importance: | + | * Importance: It was the first [[neuraminidase]] inhibitor to be approved by the FDA, followed a few months later by [[Oseltamivir]]. Newer strains of flu virus, primarily [[H1N1]], have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics. |
* See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | * See [[Pharmaceutical Drugs]] for more information about other drugs and diseases. | ||
Revision as of 11:27, 12 December 2010
|
Better Known as: Relenza
- Marketed By: GlaxoSmithKline
- Major Indication: Influenza Infection
- Drug Class: Neuraminidase Inhibitor
- Date of FDA Approval (Patent Expiration): 1999 (2016)
- 2009 Sales:$1.1 Billion
- Importance: It was the first neuraminidase inhibitor to be approved by the FDA, followed a few months later by Oseltamivir. Newer strains of flu virus, primarily H1N1, have developed varying levels of resistance to Oseltamivir, but a lesser extent to Zanamivir. Sales have increased dramatically since 2006 with scares of bird flu and swine flu pandemics.
- See Pharmaceutical Drugs for more information about other drugs and diseases.
Mechanism of Action
Pharmacokinetics
For References to Pharmacokinetic data, see: References |
||||||||||||||||||||||||||||||||||||||||||
References
